Unicycive Therapeutics (UNCY) Preferred Dividend Payments (2023 - 2024)
Unicycive Therapeutics posted quarterly Preferred Dividend Payments of $887000.0 for Q2 2024, up 47.1% year-on-year from $603000.0 in Q3 2023, and up 326.44% on a QoQ basis from $208000.0 in Q1 2024.
Unicycive Therapeutics (UNCY) has 2 years of Preferred Dividend Payments data on file, last reported at $887000.0 in Q2 2024.
- For the quarter ending Q2 2024, Preferred Dividend Payments rose 47.1% year-over-year to $887000.0; the trailing twelve-month figure through Dec 2024 stood at $1.1 million (up 26.3% YoY), and the FY2024 full-year result was $1.1 million, up 26.3% from the prior year.
- Preferred Dividend Payments for Q2 2024 stood at $887000.0, up from $208000.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $887000.0 in Q2 2024 and bottomed at $72000.0 in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 887,000.00 |
| Mar 31, 2024 | 208,000.00 |
| Sep 30, 2023 | 72,000.00 |
| Jun 30, 2023 | 603,000.00 |
| Mar 31, 2023 | 192,000.00 |